Clinical Trials Directory

Trials / Completed

CompletedNCT04697160

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL

An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study

Status
Completed
Phase
Study type
Observational
Enrollment
3,573 (actual)
Sponsor
MorphoSys AG · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.

Detailed description

This retrospective observational cohort study aims to generate a historical control consisting of R/R DLBCL patients who received currently guideline recommended therapies.

Conditions

Timeline

Start date
2020-04-01
Primary completion
2021-05-07
Completion
2021-05-07
First posted
2021-01-06
Last updated
2021-10-20

Locations

165 sites across 12 countries: United States, Australia, Austria, Canada, Denmark, France, Germany, Italy, South Korea, Spain, Taiwan, United Kingdom

Source: ClinicalTrials.gov record NCT04697160. Inclusion in this directory is not an endorsement.

Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL (NCT04697160) · Clinical Trials Directory